Atopic dermatitis (AD) is typically a big issue during early childhood. But it also afflicts up to 5% of adults. Mild cases, which are virtually always managed in primary care, are usually ...

Phase II data suggest fewer GI adverse effects when given a sequence of biologics ...

Dupilumab treatment in atopic dermatitis patients shows a 58% higher risk of developing psoriasis compared to other systemic treatments. The number needed to harm is 94, indicating a limited absolute ...

Please provide your email address to receive an email when new articles are posted on . Researchers compared dupilumab use with other and with no systemic therapy. Dupilumab inhibits IL-4 and IL-13, ...

The FDA has approved dupilumab to treat allergic fungal rhinosinusitis in adults and children ages 6 years and older.

The FDA approved Dupixent as the first treatment for allergic fungal rhinosinusitis in adults and children over six years old ...